Special Issue

Development of Radiolabeled Peptides

Message from the Guest Editor

Over the past 50 years, the development of radiopharmaceuticals for oncology has been quite significant. For both diagnostic and therapeutic purposes, imaging modalities such as PET/CT, PET/MRI, and SPECT have proven vital over the years. Novel radiopharmaceuticals are developed by integrating bench research with clinical diagnostic applications and therapeutic approaches. In terms of the development process, antibodies and peptides account for the largest segment of the market due to their clinical importance. However, unlike antibodies, small molecules and peptides can target and clear rapidly. Nonetheless, another important factor is internalization, which contributes to a longer radionuclide retention time. The journal *Pharmaceuticals* invites both reviews and original articles to highlight recent developments in research on radiolabeled peptides, both in oncology and neuroscience. The collection of manuscripts will be published as a Special Issue of the journal.

Guest Editor

Dr. Noeen Malik

MIPS-CRF, Department of Radiology, Stanford Medicine,1701 Page Mill Rd, Palo Alto, CA 94304, USA

Deadline for manuscript submissions

closed (25 March 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/145828

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

